Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1Plasma cell 1

Conditions

Multiple Myeloma 11Desmoid Tumors 6Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Paraproteinemias 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Leukemia 1Hematologic Diseases 1HIV Infections 1Granulosa cell tumor of the ovary 1Corneal Diseases 1Breast Neoplasms 1Breast Cancer Metastatic 1Blood Protein Disorders 1Advanced Solid Tumors 1AIDS-related Kaposi sarcoma 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × nirogacestat × Clear all
NCT05879146 2026-05-15

Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Tumor-Agnostic

Neoplasms

NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Hellenic Society of Hematology

Phase 1/2 Recruiting
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡